Vor Biopharma Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter ended September 30, 2023; comparisons are with the quarter and nine months ended September 30, 2022. Vor is a clinical-stage cell and genome engineering company developing treatments for blood cancers. It has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $27.6 million | $16.9 million | $73.4 million | $47.5 million |
| General and administrative expense | $7.7 million | $7.2 million | $24.5 million | $21.2 million |
| Net loss | $33.2 million | $23.8 million | $91.6 million | $68.2 million |
| Net loss per share, diluted | $0.49 | $0.63 | $1.37 | $1.81 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $76.3 million | $66.8 million |
At September 30, 2023, cash and cash equivalents were $45.0 million and marketable securities were $115.1 million, totaling $160.1 million; restricted cash was an additional $2.4 million. Total assets were $223.0 million, total liabilities $48.2 million, and stockholders’ equity $174.8 million. Liabilities included $36.6 million of operating lease obligations; the filing reports no debt balance. Gross margin is not applicable because Vor had no revenue.
For the nine-month period, investing activities provided $60.7 million, primarily reflecting maturities of marketable securities, while financing activities provided $2.9 million. Cash, cash equivalents and restricted cash decreased by $12.7 million to $47.4 million. Vor raised $4.7 million net through its at-the-market (ATM) facility during the period; $120.2 million remained available under that facility at quarter-end.
Changes versus prior comparable periods
- Q3 operating expenses rose $11.2 million year over year, and net loss increased $9.4 million. For the first nine months, operating expenses rose $29.2 million and net loss increased $23.4 million.
- Higher R&D spending drove most of the expense increase, including clinical and manufacturing work, platform studies, the Editas Medicine license, personnel, and expanded laboratory and cGMP facility costs.
- Interest income increased to $2.1 million in Q3 and $6.3 million for the nine months, versus $0.3 million and $0.5 million, respectively, reflecting higher interest earned on cash and investments.
- Weighted-average shares outstanding increased materially year over year, from 38.0 million to 67.6 million in Q3 and from 37.6 million to 67.0 million for the nine months. The lower reported loss per share therefore does not indicate improved operating performance.
Outlook, developments and risks
- Management estimated that September 30 cash, cash equivalents and marketable securities would fund operating expenses and capital requirements into the first quarter of 2025. It cautioned that assumptions may prove incorrect and additional capital will be needed; the filing also warns that financing may be unavailable or dilutive.
- Management expects significant ongoing operating losses and substantial future spending, particularly for R&D, clinical trials, manufacturing and facilities. The company does not expect near-term product revenue.
- Trem-cel is being studied in the Phase 1/2a VBP101 trial with Mylotarg. Vor expected to provide additional engraftment and hematologic-protection data by a November 2023 conference.
- VCAR33 ALLO’s IND was cleared in June 2023, and its Phase 1/2 VBP301 trial was enrolling patients. Vor planned to gather initial trem-cel and VCAR33 ALLO data before submitting an IND for the combined treatment system.
- The filing reports November 2023 VCAR33 AUTO trial data released by external investigators: 2 of 5 evaluable patients at the highest dose achieved complete remission; 4 of 19 patients had cytokine release syndrome of Grade 3 or higher. The NMDP controls this trial, and Vor does not control its design, conduct or data analysis.
- Vor said its in-house manufacturing facility completed cGMP qualification for VCAR33 ALLO clinical manufacturing; trem-cel engineering runs were completed, with in-house manufacturing planned to begin in 2023 and third-party manufacturing retained for redundancy.
- Material uncertainties include clinical and regulatory outcomes, patient enrollment, manufacturing execution, reliance on third parties and licensed intellectual property, and the need for further financing. Vor reported no material change to its previously disclosed risk factors, no material legal proceedings, and effective disclosure controls.
Important facts for investors to verify
- Whether clinical trial updates for trem-cel and VCAR33 support safety, efficacy, engraftment and the proposed combination strategy.
- Whether management’s cash runway estimate to Q1 2025 remains achievable as trial, manufacturing and facility spending continues.
- Future cash burn, financing needs, ATM usage and resulting dilution; shares outstanding were 67.8 million at September 30, 2023.
- Progress and reliability of in-house clinical manufacturing, including planned trem-cel tech transfer and third-party backup.
- Any subsequent changes to trial timelines, financing availability, licensing obligations or material risks.